Construction, Validation, and Visualization of Two Web-Based Nomograms to Predict Overall and Cancer-Specific Survival in Patients with Gastric Cancer and Lung Metastases

Table 1

Baseline data of clinicopathological characteristics of patients with GCLM in OS group.

Variables	Total cohort (N = 640)		Training cohort (N = 448)		Validation cohort (N = 192)
	n	%	n	%	n	%
Age
<60	219	34.2	158	35.3	61	31.8
≥60	421	65.8	290	64.7	131	68.2
Race
Black	75	11.7	53	11.8	22	11.5
Other	81	12.7	51	11.4	30	15.6
White	484	75.6	344	76.8	140	72.9
Sex
Female	194	30.3	127	28.3	67	34.9
Male	446	69.7	321	71.7	125	65.1
Histologic type
Adenocarcinoma	407	63.6	288	64.3	119	62.0
Signet ring cell	94	14.7	66	14.7	28	14.6
Intestinal type	42	6.6	26	5.8	16	8.3
Other	97	15.2	68	15.2	29	15.1
T stage
T1	252	39.4	168	37.5	84	43.8
T2	40	6.3	28	6.3	12	6.3
T3	147	23	106	23.7	41	21.4
T4	201	31.4	146	32.6	55	28.6
N stage
N0	262	40.9	185	41.3	77	40.1
N1	292	45.6	198	44.2	94	49.0
N2	43	6.7	35	7.8	8	4.2
N3	43	6.7	30	6.7	13	6.8
Grade
Grade I	26	4.1	16	3.6	10	5.2
Grade II	178	27.8	124	27.7	54	28.1
Grade III	426	66.6	302	67.4	124	64.6
Grade IV	10	1.6	6	1.3	4	2.1
Bone metastasis
No	526	82.2	372	83	154	80.2
Yes	114	17.8	76	17	38	19.8
Liver metastasis
No	325	50.8	222	49.6	103	53.6
Yes	315	49.2	226	50.4	89	46.4
Brain metastasis
No	622	97.2	436	97.3	186	96.9
Yes	18	2.8	12	2.7	6	3.1
Primary site
Cardia	291	45.5	201	44.9	90	46.9
Fundus	35	5.5	22	4.9	13	6.8
Body	44	6.9	31	6.9	13	6.8
Gastric antrum	74	11.6	53	11.8	21	10.9
Lesser	28	4.4	21	4.7	7	3.6
Greater	30	4.7	22	4.9	8	4.2
Other	138	21.6	98	21.9	40	20.8
Radiotherapy
No	492	76.9	348	77.7	144	75.0
Yes	148	23.1	100	22.3	48	25.0
Chemotherapy
No	256	40	179	40	77	40.1
Yes	384	60	269	60	115	59.9
Surgery
No	580	90.6	407	90.8	173	90.1
Yes	60	9.4	41	9.2	19	9.9
Marital status
No	255	39.8	182	40.6	73	38.0
Yes	385	60.2	266	59.4	119	62.0
Insurance
No	37	5.8	30	6.7	7	3.6
Yes	603	94.2	418	93.3	185	96.4